Checkpoint inhibitors in patients with advanced, refractory biliary tract cancers

被引：0
|
作者：
Liddell, S. [1 ]
Wintheiser, G. [1 ]
Jin, Z. [1 ]
Tran, N. [1 ]
Mahipal, A. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-278
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [41] Quality of Life and Symptom Management in Advanced Biliary Tract Cancers
    Hunter, Lindsay A.
    Soares, Heloisa P.
    CANCERS, 2021, 13 (20)
  • [42] Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers
    Verderame, F.
    Russo, A.
    Di Leo, R.
    Badalamenti, G.
    Santangelo, D.
    Cicero, G.
    Valerio, M. R.
    Gulotta, G.
    Tomasello, G.
    Gebbia, N.
    Fulfaro, F.
    ANNALS OF ONCOLOGY, 2006, 17 : VII68 - VII72
  • [43] Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers
    Mody, Kabir
    Kasi, Pashtoon M.
    Yang, JuDong
    Surapaneni, Phani Keerthi
    Bekaii-Saab, Tanios
    Ahn, Daniel H.
    Mahipal, Amit
    Sonbol, Mohamad B.
    Starr, Jason S.
    Roberts, Ali
    Nagy, Rebecca
    Lanman, Richard
    Borad, Mitesh J.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 9
  • [44] Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma
    Swami, Umang
    Haaland, Benjamin
    Kessel, Adam
    Nussenzveig, Roberto
    Maughan, Benjamin Louis
    Esther, John
    Sirohi, Deepika
    Pal, Sumanta K.
    Grivas, Petros
    Agarwal, Neeraj
    JOURNAL OF UROLOGY, 2021, 205 (03): : 709 - 717
  • [45] Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
    Li, Jingjing
    Wei, Qing
    Wu, Xiaoying
    Sima, Jun
    Xu, Qi
    Wu, Mengmeng
    Wang, Fufeng
    Mou, Haibo
    Hu, Hanguang
    Zhao, Jianguo
    Li, Da
    Hu, Jinlin
    Zhang, Lingnan
    Zhu, Xiu
    Chen, Lei
    Luo, Cong
    Yan, Junrong
    He, Jiachen
    Ma, Yutong
    Shao, Yang
    Wu, Wei
    Ying, Jieer
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (04):
  • [46] Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    LIVER INTERNATIONAL, 2023, 43 (10) : 2292 - 2301
  • [47] The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
    Jeong, Sun Young
    Hong, Jung Yong
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Jang, Jae Yeon
    Jeon, Youngkyung
    Kim, Seung Tae
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [48] Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers
    Mathers, Brittney
    Abadi, Shirin
    Davies, Janine M.
    McIntyre, Connor
    Ho, Cheryl
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 1381 - 1386
  • [49] Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
    James J. Harding
    Sarina A. Piha-Paul
    Ronak H. Shah
    Jessica J. Murphy
    James M. Cleary
    Geoffrey I. Shapiro
    David I. Quinn
    Irene Braña
    Victor Moreno
    Mitesh Borad
    Sherene Loi
    Iben Spanggaard
    Haeseong Park
    James M. Ford
    Mónica Arnedos
    Salomon M. Stemmer
    Christelle de la Fouchardiere
    Christos Fountzilas
    Jie Zhang
    Daniel DiPrimeo
    Casey Savin
    S. Duygu Selcuklu
    Michael F. Berger
    Lisa D. Eli
    Funda Meric-Bernstam
    Komal Jhaveri
    David B. Solit
    Ghassan K. Abou-Alfa
    Nature Communications, 14
  • [50] Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers
    Chapin, William Joseph
    Agarwal, Parul
    DiCicco, Lisa
    Palmer, Rayleigh
    Cenou, Nadia
    Huang, Alexander Chan Chi
    Karasic, Thomas Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345